biostudies-literatureBoele FWEuropean Organisation for Research and Treatment of Cancer2959-2974https://www.ebi.ac.uk/biostudies/studies/S-EPMC12908480biostudies-literatureUnknown27(11)<h4>Background</h4>Patients with oligodendroglioma have a relatively favorable prognosis. The long-term impacts of the tumor itself and its treatment on health-related quality of life (HRQOL) and cognition remain largely unclear. We investigated associations between treatment and functioning of survivors of oligodendroglioma.<h4>Methods</h4>In this cross-sectional observational study, patients with oligodendroglioma, isocitrate dehydrogenase-mutant and 1p/19q-codeleted, diagnosed ≥ 5 years ago, were recruited. Patients completed patient-reported outcome measures (EORTC QLQ-C30; BN20; MOS Cognitive Complaints Scale) and cognitive tests (HVLT-R, TMT, COWAT). Associations between HRQOL and cognition outcomes, and clinical variables (time since diagnosis; age at diagnosis; progression; tumor lNeuro-oncologyHealth-related quality of life and cognitive functioning in survivors of oligodendroglioma: An international cross-sectional investigation.PMC12908480004-2018Welsh LWeller MDehais CRyden IJena RNoel GMuhic AAshkan KVauleon EHertler CDucray FDesideri IMehta SBurger MCBoele FWHaldbo-Classen LSanghera PDarlix ATabouret EFrances SMHrab IDahlrot RHHerrlinger UKlein MKazda TMalmstrom ADurando XCartalat SLawson McLean AMcBain CGuerdoux ERazis EBourg VRenovanz MFoweraker KWerner JMEngelhardt JLord HfalseHealth-related quality of life and cognitive functioning in survivors of oligodendroglioma: An international cross-sectional investigation.<h4>Background</h4>Patients with oligodendroglioma have a relatively favorable prognosis. The long-term impacts of the tumor itself and its treatment on health-related quality of life (HRQOL) and cognition remain largely unclear. We investigated associations between treatment and functioning of survivors of oligodendroglioma.<h4>Methods</h4>In this cross-sectional observational study, patients with oligodendroglioma, isocitrate dehydrogenase-mutant and 1p/19q-codeleted, diagnosed ≥ 5 years ago, were recruited. Patients completed patient-reported outcome measures (EORTC QLQ-C30; BN20; MOS Cognitive Complaints Scale) and cognitive tests (HVLT-R, TMT, COWAT). Associations between HRQOL and cognition outcomes, and clinical variables (time since diagnosis; age at diagnosis; progression; tumor l2025-01-01T00:00:00Z2025 Nov2026-07-16T05:05:25.254Z2026-07-09T10:38:07.178ZS-EPMC129084804069247710.1093/neuonc/noaf172